Cargando…

Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer’s disease and mild cognitive impairment

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with clinical, biological, and pathological features occurring along a continuum from normal to end-stage disease. Currently, the diagnosis of AD depends on clinical assessments and post-mortem neuropathology, which is unbenefited...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Weilin, Lin, Huawei, He, Xiaojun, Chen, Lewen, Dai, Yaling, Jia, Weiwei, Xue, Xiehua, Tao, Jing, Chen, Lidian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7190828/
https://www.ncbi.nlm.nih.gov/pubmed/32350238
http://dx.doi.org/10.1038/s41398-020-0801-2
_version_ 1783527765352382464
author Liu, Weilin
Lin, Huawei
He, Xiaojun
Chen, Lewen
Dai, Yaling
Jia, Weiwei
Xue, Xiehua
Tao, Jing
Chen, Lidian
author_facet Liu, Weilin
Lin, Huawei
He, Xiaojun
Chen, Lewen
Dai, Yaling
Jia, Weiwei
Xue, Xiehua
Tao, Jing
Chen, Lidian
author_sort Liu, Weilin
collection PubMed
description Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with clinical, biological, and pathological features occurring along a continuum from normal to end-stage disease. Currently, the diagnosis of AD depends on clinical assessments and post-mortem neuropathology, which is unbenefited early diagnosis and progressive monitoring. In recent years, clinical studies have reported that the level of cerebrospinal fluid (CSF) and blood neurogranin (Ng) are closely related to the occurrence and subsequent progression of AD. Therefore, the study used meta-analysis to identify the CSF and blood Ng levels for the development of diagnosis biomarker of patients with AD and mild cognitive impairment (MCI). We searched the Pubmed, Embase, Cochrane Library, and Web of Science databases. A total of 24 articles eligible for inclusion and exclusion criteria were assessed, including 4661 individuals, consisting of 1518 AD patients, 1501 MCI patients, and 1642 healthy control subjects. The level of CSF Ng significantly increased in patients with AD and MCI compared with healthy control subjects (SMD: 0.84 [95% CI: 0.70–0.98], P < 0.001; SMD: 0.53 [95% CI: 0.40–0.66], P = 0.008), and higher in AD patients than in MCI patients (SMD: 0.18 [95% CI: 0.07–0.30], P = 0.002), and CSF Ng level of patients with MCI-AD who progressed from MCI to AD was significantly higher than that of patients with stable MCI (sMCI) (SMD: 0.71 [95% CI: 0.25–1.16], P = 0.002). Moreover, the concentration of Ng in blood plasma exosomes of patients with AD and MCI was lower than that of healthy control subjects (SMD: −6.657 [95% CI: −10.558 to −2.755], P = 0.001; and SMD: −3.64 [95% CI: −6.50 to −0.78], P = 0.013), and which in patients with AD and MCI-AD were also lower than those in patients with sMCI (P < 0.001). Furthermore, regression analysis showed a negative relationship between MMSE scores and CSF Ng levels in MCI patients (slope = −0.249 [95% CI: −0.003 to −0.495], P = 0.047). Therefore, the Ng levels increased in CSF, but decreased in blood plasma exosomes of patients with AD and MCI-AD, and highly associated with cognitive declines. These findings provide the clinical evidence that CSF and blood exosomes Ng can be used as a cognitive biomarker for AD and MCI-AD, and further studies are needed to define the specific range of Ng values for diagnosis at the different stages of AD.
format Online
Article
Text
id pubmed-7190828
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-71908282020-05-06 Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer’s disease and mild cognitive impairment Liu, Weilin Lin, Huawei He, Xiaojun Chen, Lewen Dai, Yaling Jia, Weiwei Xue, Xiehua Tao, Jing Chen, Lidian Transl Psychiatry Article Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with clinical, biological, and pathological features occurring along a continuum from normal to end-stage disease. Currently, the diagnosis of AD depends on clinical assessments and post-mortem neuropathology, which is unbenefited early diagnosis and progressive monitoring. In recent years, clinical studies have reported that the level of cerebrospinal fluid (CSF) and blood neurogranin (Ng) are closely related to the occurrence and subsequent progression of AD. Therefore, the study used meta-analysis to identify the CSF and blood Ng levels for the development of diagnosis biomarker of patients with AD and mild cognitive impairment (MCI). We searched the Pubmed, Embase, Cochrane Library, and Web of Science databases. A total of 24 articles eligible for inclusion and exclusion criteria were assessed, including 4661 individuals, consisting of 1518 AD patients, 1501 MCI patients, and 1642 healthy control subjects. The level of CSF Ng significantly increased in patients with AD and MCI compared with healthy control subjects (SMD: 0.84 [95% CI: 0.70–0.98], P < 0.001; SMD: 0.53 [95% CI: 0.40–0.66], P = 0.008), and higher in AD patients than in MCI patients (SMD: 0.18 [95% CI: 0.07–0.30], P = 0.002), and CSF Ng level of patients with MCI-AD who progressed from MCI to AD was significantly higher than that of patients with stable MCI (sMCI) (SMD: 0.71 [95% CI: 0.25–1.16], P = 0.002). Moreover, the concentration of Ng in blood plasma exosomes of patients with AD and MCI was lower than that of healthy control subjects (SMD: −6.657 [95% CI: −10.558 to −2.755], P = 0.001; and SMD: −3.64 [95% CI: −6.50 to −0.78], P = 0.013), and which in patients with AD and MCI-AD were also lower than those in patients with sMCI (P < 0.001). Furthermore, regression analysis showed a negative relationship between MMSE scores and CSF Ng levels in MCI patients (slope = −0.249 [95% CI: −0.003 to −0.495], P = 0.047). Therefore, the Ng levels increased in CSF, but decreased in blood plasma exosomes of patients with AD and MCI-AD, and highly associated with cognitive declines. These findings provide the clinical evidence that CSF and blood exosomes Ng can be used as a cognitive biomarker for AD and MCI-AD, and further studies are needed to define the specific range of Ng values for diagnosis at the different stages of AD. Nature Publishing Group UK 2020-04-29 /pmc/articles/PMC7190828/ /pubmed/32350238 http://dx.doi.org/10.1038/s41398-020-0801-2 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Liu, Weilin
Lin, Huawei
He, Xiaojun
Chen, Lewen
Dai, Yaling
Jia, Weiwei
Xue, Xiehua
Tao, Jing
Chen, Lidian
Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer’s disease and mild cognitive impairment
title Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer’s disease and mild cognitive impairment
title_full Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer’s disease and mild cognitive impairment
title_fullStr Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer’s disease and mild cognitive impairment
title_full_unstemmed Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer’s disease and mild cognitive impairment
title_short Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer’s disease and mild cognitive impairment
title_sort neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for alzheimer’s disease and mild cognitive impairment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7190828/
https://www.ncbi.nlm.nih.gov/pubmed/32350238
http://dx.doi.org/10.1038/s41398-020-0801-2
work_keys_str_mv AT liuweilin neurograninasacognitivebiomarkerincerebrospinalfluidandbloodexosomesforalzheimersdiseaseandmildcognitiveimpairment
AT linhuawei neurograninasacognitivebiomarkerincerebrospinalfluidandbloodexosomesforalzheimersdiseaseandmildcognitiveimpairment
AT hexiaojun neurograninasacognitivebiomarkerincerebrospinalfluidandbloodexosomesforalzheimersdiseaseandmildcognitiveimpairment
AT chenlewen neurograninasacognitivebiomarkerincerebrospinalfluidandbloodexosomesforalzheimersdiseaseandmildcognitiveimpairment
AT daiyaling neurograninasacognitivebiomarkerincerebrospinalfluidandbloodexosomesforalzheimersdiseaseandmildcognitiveimpairment
AT jiaweiwei neurograninasacognitivebiomarkerincerebrospinalfluidandbloodexosomesforalzheimersdiseaseandmildcognitiveimpairment
AT xuexiehua neurograninasacognitivebiomarkerincerebrospinalfluidandbloodexosomesforalzheimersdiseaseandmildcognitiveimpairment
AT taojing neurograninasacognitivebiomarkerincerebrospinalfluidandbloodexosomesforalzheimersdiseaseandmildcognitiveimpairment
AT chenlidian neurograninasacognitivebiomarkerincerebrospinalfluidandbloodexosomesforalzheimersdiseaseandmildcognitiveimpairment